Literature DB >> 21699946

Assessing the potency of oral polio vaccine kept outside of the cold chain during a national immunization campaign in Chad.

Simona Zipursky1, Liliane Boualam, Dah Ould Cheikh, Jacqueline Fournier-Caruana, Djabar Hamid, Mathias Janssen, Umit Kartoglu, Genevieve Waeterloos, Olivier Ronveaux.   

Abstract

This study is the first systematic documentation of the potency of monovalent oral polio vaccine type 3 (mOPV3) kept at ambient temperatures during a polio immunization campaign in Chad. During the study test vials were exposed to temperatures of up to 47.1 °C, and kept outside of the 2-8 °C range for a maximum of 86.9 hours. Post-campaign laboratory testing confirmed that the test vials were still potent, and in conformity with the defined release specifications. Further, the Vaccine Vial Monitors performed as expected, giving an early warning indication of when cumulative exposure to heat reached levels that may have negatively affected the vaccine's potency. This study provides proof-of-concept evidence that certain types of OPV remain potent and thus can be kept, for limited periods of time, as well as administered at ambient temperatures.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Mesh:

Substances:

Year:  2011        PMID: 21699946     DOI: 10.1016/j.vaccine.2011.06.011

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

1.  Correlation Study of the Most Important Environmental Influencing Factors on the Razi MMR Vaccine.

Authors:  S Soleimani; S Rashid
Journal:  Arch Razi Inst       Date:  2021-11-30

2.  Who is running faster, the virus or the vaccine?

Authors:  Han Dai; Jie Han; Eric Lichtfouse
Journal:  Environ Chem Lett       Date:  2020-10-15       Impact factor: 9.027

3.  Economic benefits of keeping vaccines at ambient temperature during mass vaccination: the case of meningitis A vaccine in Chad.

Authors:  Patrick Lydon; Simona Zipursky; Carole Tevi-Benissan; Mamoudou Harouna Djingarey; Placide Gbedonou; Brahim Oumar Youssouf; Michel Zaffran
Journal:  Bull World Health Organ       Date:  2013-11-04       Impact factor: 9.408

4.  From regional pulse vaccination to global disease eradication: insights from a mathematical model of poliomyelitis.

Authors:  Cameron J Browne; Robert J Smith; Lydia Bourouiba
Journal:  J Math Biol       Date:  2014-07-30       Impact factor: 2.164

Review 5.  Determinants of effective vaccine coverage in low and middle-income countries: a systematic review and interpretive synthesis.

Authors:  David E Phillips; Joseph L Dieleman; Stephen S Lim; Jessica Shearer
Journal:  BMC Health Serv Res       Date:  2017-09-26       Impact factor: 2.655

6.  Rational design of heat stable lyophilized rotavirus vaccine formulations.

Authors:  Madhu Madan; Deepa Sikriwal; Gaurav Sharma; Nidhi Shukla; Ashwani Kumar Mandyal; Sachin Kale; Davinder Gill
Journal:  Hum Vaccin Immunother       Date:  2018-07-11       Impact factor: 3.452

7.  Development of a thermostable nanoemulsion adjuvanted vaccine against tuberculosis using a design-of-experiments approach.

Authors:  Ryan M Kramer; Michelle C Archer; Mark T Orr; Natasha Dubois Cauwelaert; Elyse A Beebe; Po-Wei D Huang; Quinton M Dowling; Alicia M Schwartz; Dawn M Fedor; Thomas S Vedvick; Christopher B Fox
Journal:  Int J Nanomedicine       Date:  2018-06-26

Review 8.  Tools and approaches to ensure quality of vaccines throughout the cold chain.

Authors:  Umit Kartoglu; Julie Milstien
Journal:  Expert Rev Vaccines       Date:  2014-05-28       Impact factor: 5.217

9.  Can thermostable vaccines help address cold-chain challenges? Results from stakeholder interviews in six low- and middle-income countries.

Authors:  Debra D Kristensen; Tina Lorenson; Kate Bartholomew; Shirley Villadiego
Journal:  Vaccine       Date:  2016-01-08       Impact factor: 3.641

10.  Benefits of using vaccines out of the cold chain: delivering meningitis A vaccine in a controlled temperature chain during the mass immunization campaign in Benin.

Authors:  Simona Zipursky; Mamoudou Harouna Djingarey; Jean-Claude Lodjo; Laifoya Olodo; Sylvestre Tiendrebeogo; Olivier Ronveaux
Journal:  Vaccine       Date:  2014-02-19       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.